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MicroRNAs are a recently discovered class of posttranscriptional regulators of gene expression with critical functions in health
and disease. Psoriasis is the most prevalent chronic inflammatory skin disease in adults, with a substantial negative impact on
the patients’ quality of life. Here we show for the first time that psoriasis-affected skin has a specific microRNA expression
profile when compared with healthy human skin or with another chronic inflammatory skin disease, atopic eczema. Among the
psoriasis-specific microRNAs, we identified leukocyte-derived microRNAs and one keratinocyte-derived microRNA, miR-203. In
a panel of 21 different human organs and tissues, miR-203 showed a highly skin-specific expression profile. Among the cellular
constituents of the skin, it was exclusively expressed by keratinocytes. The up-regulation of miR-203 in psoriatic plaques was
concurrent with the down-regulation of an evolutionary conserved target of miR-203, suppressor of cytokine signaling 3
(SOCS-3), which is involved in inflammatory responses and keratinocyte functions. Our results suggest that microRNA
deregulation is involved in the pathogenesis of psoriasis and contributes to the dysfunction of the cross talk between resident
and infiltrating cells. Taken together, a new layer of regulatory mechanisms is involved in the pathogenesis of chronic
inflammatory skin diseases.
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INTRODUCTION
MicroRNAs (miRNAs) are ,22 nt noncoding RNAs that can
suppress the expression of protein-coding genes by targeting
cognate messenger RNAs for translational repression or, less
frequently, degradation [1,2]. In the human genome, miRNAs
comprise 1-5% of all genes making them the most abundant class
of regulators. The high sequence conservation of many miRNAs
among distantly related organisms suggests strong evolutionary
pressure and participation in essential processes [1]. Indeed,
miRNAs have regulatory roles in development, differentiation,
organogenesis, stem cell and germline proliferation, growth
control and apoptosis. Moreover, deregulation of miRNA
expression may contribute to human diseases; in particular,
miRNAs are often aberrantly expressed or mutated in cancer [3].
Thus, miRNAs represent important targets for potential thera-
peutic and diagnostic agents [4].
While miRNAs are known to regulate cell growth, apoptosis,
differentiation and morphological development, neither their
expression nor roles have been characterized in skin diseases.
Psoriasis is the most prevalent chronic inflammatory skin disease in
adults affecting 1-3% of the population worldwide with a sub-
stantial negative impact on the patients’ quality of life [5]. A
complex interplay of genetic and environmental factors together
with immunoregulatory abnormalities is thought to play a critical
role in the pathogenesis of this disease. Keratinocytes and
infiltrating immune cells play a cooperative role in the formation
of psoriasis lesions; however, the exact molecular mechanisms
regulating the complex interactions among resident skin cells and
infiltrating immune cells are still not completely understood.
Investigations analyzing the molecular background of psoriasis
have identified hundreds of disease-associated genes and proteins
with aberrant expression [6–8], however, our understanding about
the regulatory networks underlying the altered expression of these
genes is far from being complete.
Here, we demonstrate that psoriasis is characterized by a specific
miRNA expression profile that differs from that of healthy skin or
another chronic inflammatory disease, atopic eczema. Among the
miRNAs overexpressed in psoriasis, we identified a keratinocyte-
specific miRNA (miR-203) and a leukocyte-derived miRNA (miR-
146a). The up-regulation of miR-203 in psoriatic plaques was
concurrent with the down-regulation of an evolutionary conserved
target of miR-203, suppressor of cytokine signaling 3 (SOCS-3),
which is involved in inflammatory responses and keratinocyte
functions. These results suggest that miRNAs contribute to
psoriasis pathogenesis by modulating protein expression and
cellular functions in both keratinocytes and infiltrating immune
cells. Thus, our findings reveal a new layer of regulatory
mechanisms in the pathogenesis of chronic inflammatory skin
diseases.
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A characteristic miRNA signature identified in
psoriasis skin
At present, the expression and function of miRNAs in human skin
is largely unknown. To determine whether miRNAs are involved
in the pathogenesis of psoriasis, we performed a comprehensive
analysis of all human miRNAs registered in mirBase 8.0 (342
known human miRNAs) in skin lesions of patients with psoriasis
(n=3) and compared it to healthy human skin (n=4) or to lesional
skin from patients with a nonpsoriatic chronic inflammatory skin
disease, atopic eczema (n=3). Analysis of the microarray data
showed that miRNAs are expressed in a non-random manner in
psoriasis, healthy, or atopic eczema skin (Fig. 1A). Using the
Significance Analysis of Microarrays (SAM) algorithm [9], we
identified 29 genes that were consistently differentially expressed
between psoriasis and healthy skin (Fig. 1B). Among the genes
identified in the SAM analysis there were (I) miRNAs specifically
up-regulated in psoriasis (e.g. miR-203), (II) miRNAs with
increased expression in both psoriasis and atopic eczema (e.g.
miR-21), (III) miRNAs specifically down-regulated in psoriasis
(e.g. miR-99b), and (IV) miRNAs uniformly down-regulated in
both skin diseases (e.g. miR-122a), as compared to healthy skin.
To confirm the results obtained by microarray profiling, we
performed quantitative real-time PCR analysis of miR-203, miR-
146a, miR-21 and miR-125b expression on RNA samples
obtained from lesional skin of patients with psoriasis (n=25),
healthy skin (n=26) or atopic eczema lesions (n=20). For this, we
used primers designed to amplify specifically the mature, bi-
ologically active form of these miRNAs (Fig. 1C). In accordance
Figure 1. MicroRNA expression profiling in psoriasis, atopic eczema and healthy skin. (A) microRNA (miRNA) array comparison of skin from healthy
individuals (H, n=4) and lesional skin from patients with psoriasis (PSO, n=3) and atopic eczema (AE, n=3). Total RNA from skin biopsies was labeled
and hybridized to microarrays containing probes corresponding to known miRNA sequences. The heat map summarizes the biological replicates for
the skin specimens, and four technical replicates for each set. Color intensity is scaled within each row so that the highest expression value
corresponds to bright red and the lowest to bright green. Gene names are listed to the right. (B) miRNAs showing more than 1.7-fold change
between psoriasis and healthy skin (left) and atopic eczema and healthy skin (right) according to the SAM algorithm. miRNAs that are over-expressed
in both psoriasis and in atopic eczema are highlighted in yellow, miRNAs that are down-regulated in both diseases are highlighted in blue. (C) The
expressions of the functionally active, mature forms of four miRNAs were analyzed using quantitative real-time PCR in the skin of 26 healthy
individuals, and lesional skin samples of 20 patients with atopic eczema and 25 patients with psoriasis. The results for individual patients and mean
are shown. Data are expressed in relative units compared to U48 RNA. ***p,0.001, **p,0.01.
doi:10.1371/journal.pone.0000610.g001
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showed significantly (p,0.001) increased miR-203 levels in
psoriasis skin when compared with healthy skin. Moreover,
miR-203 was expressed at a significantly (p,0.01) higher level
in psoriasis than in atopic eczema skin specimen. No significant
up-regulation of miR-203 was observed in atopic eczema skin
lesions compared with healthy skin (Fig. 1C). Similarly, miR-146a
was significantly over-expressed in psoriatic lesional skin (p,0.001)
but not in atopic eczema lesions when compared with healthy skin
(Fig. 1C). Furthermore, miR-146a was expressed at a significantly
(p,0.001) higher level in psoriasis than in atopic eczema skin
samples. The psoriasis-specific overexpression of miR-203 and
miR-146 suggests that they may play specific roles in the
pathogenesis of psoriasis and not only a general role in skin
inflammation. In contrast to miR-203 and miR-146a, miR-21 was
significantly up-regulated both in psoriasis (p,0.001) and atopic
eczema (p,0.001) as compared with healthy skin. miR-125b
showed the opposite expression pattern to miR-21: the level of this
miRNA significantly (p,0.001 for both) decreased both in
psoriasis and atopic eczema. Taken together, psoriasis is
characterized by a distinct miRNA expression profile in
comparison with healthy skin or with atopic eczema.
miR-203, miR-146a, miR-21 and miR-125b show
distinct expression patterns in human organs and
cells types
At present, the expression pattern of the miRNAs we identified in
skin is largely unknown in different organs and tissues. To obtain
further insights into the function of the psoriasis-associated miRNAs,
we systematically analyzed the expression of miR-203, miR-146a,
miR-21 and miR-125b in skin and a panel of 20 additional human
organs obtained from healthy individuals (Fig. 2). Quantitative real-
time PCR analysis showed that miR-203, a miRNA specifically up-
regulated in psoriasis, was expressed more than 100-fold higher in
skin compared with most other organs. In addition to skin, miR-203
was only expressed at lower levels in organs that also contain
squamous epithelium, esophagus and cervix. These findings suggest
a specific function for this miRNA in the formation or function of
squamous epithelia. In contrast to miR-203, the mature forms of
miR-146a, miR-21 and miR-125b were detected in all studied
organs, however, their expression showed distinct patterns. MiR-
146a was highly expressed in organs containing significant number
of leukocytes such as the thymus and the spleen, and showed low
expression in healthy skin, suggesting that infiltrating cells express
miR-146a in the skin (Fig. 2). MiR-21 showed highest expression in
the lung, trachea, colon, prostate and bladder (Fig. 2), while miR-
125b, a miRNA downregulated in both psoriasis and atopic eczema,
was expressed mostly in organs that contain cells of ectodermal
origin, including cervix, brain and bladder.
In psoriasis, there is evidence for the pathogenic relevance of
several different cell types that normally occur in skin: keratino-
cytes [12], fibroblasts [13], monocyte-derived immunocytes
[11,14], T cells [15], and mast cells [16]. Therefore it is likely
that this disease is the outcome of aberrantly activated mechanisms
that do not necessarily depend on one single cell type but involve
a variety of different cell populations [11,17]. To identify the cell
types expressing the identified psoriasis-associated miRNAs in the
Figure 2. Expression of miR-203, miR-146a, miR-21 and miR-125b in human organs. The expressions of the functionally active, mature forms of
miR-203, miR-21, miR-146a and miR-125b were analyzed using quantitative real-time PCR in 20 healthy organs and tissues (each a pool of three
donors) as well as in healthy skin (n=26), lesional atopic eczema (n=20) and psoriasis (n=25) skin samples. Error bars represent the standard error of
the mean. Data are expressed in relative units compared to U48 RNA. ***p,0.001, **p,0.01.
doi:10.1371/journal.pone.0000610.g002
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146a, miR-21 and miR-125b in a panel of cells present in healthy
and/or inflamed skin including both resident cells (keratinocytes,
dermal fibroblasts and melanocytes) and leukocyte/immune cell
subsets (CD4
+, CD8
+ and CD4
+CD25
high T cell subsets, NK cells,
granulocytes, B cells, dendritic cells and mast cells). In accordance
with their expression profiles in different organs, the identified
miRNAs showed a distinctive expression pattern in the studied cell
types. miR-203, which was specifically expressed in skin among 21
different human organs, showed a keratinocyte-specific expression
being virtually absent in all other cell types analyzed (Fig. 3). This
observation suggests a role for this miRNA in keratinocyte
functions in healthy skin as well as in psoriasis. By contrast,
miR-146a was absent from keratinocytes and dermal fibroblasts,
and it was preferentially expressed by immune cells (Fig. 3), in
accordance with its high expression in immune organs (Fig. 2) and
in the psoriatic inflamed skin. In particular, CD4
+CD25
high
regulatory T cells, monocyte-derived dendritic cells (MDDCs) and
mast cells expressed miR-146a at a high level. The abundant
expression of miR-146a in CD4
+CD25
high cells suggests that this
miRNA might influence the function of regulatory T cells in
psoriatic skin. miR-21, a microRNA upregulated in both psoriasis
and atopic eczema, was expressed both by structural and
inflammatory cells (Fig. 2). The expression pattern of miR-125b
was complementary to that of mir-146a: it was expressed at a very
low level in inflammatory cells in comparison to structural cells:
fibroblasts, keratinocytes and melanocytes (Fig. 2).
It is widely accepted that psoriasis is not a disease caused by one
cell type but a consequence of impaired cross talk between the
immune system and the structural cells of the skin [11]. Investigating
thecellulardistributionofmiRNAsderegulatedinpsoriasiswefound
that these master switches of gene expression are expressed in cells
with key roles in the pathogenesis of psoriasis. Deregulation of both
keratinocyte- and leukocyte-specific miRNAs in psoriasis indicates
that altered miRNA-mediated gene regulation may contribute to the
disturbed cross talk between keratinocytes and immune cells. One of
the most important mediators in leukocyte-keratinocyte interactions
in psoriasis is tumor necrosis factor alpha (TNF-a)a se v i d e n c e db y
the effectiveness of TNF-a inhibitors in the treatment of psoriasis
[11]. Interestingly, a recent study showed that miR-146a, one of the
psoriasis-specific miRNAs, inhibits the expression of IRAK-1 and
TRAF-6proteinsbothofwhichareregulatorsoftheTNF-asignaling
pathway [10]. Hence, it is conceivable that miR-146a is involved in
the pathogenesis of psoriasis via the modulation of TNF-a signaling
in the skin. In contrast to miR-146, nothing is known about the
function of the keratinocyte-specific miRNA, miR-203.
Figure 3. Expression of miR-203, miR-146a, miR-21 and miR-125b in the cellular constituents of the skin. The expressions of the functionally
active, mature forms of miR-203, miR-146a, miR-21 and miR-125b were analyzed in the cellular constituents of the skin including primary adult
keratinocytes, dermal fibroblasts, melanocytes, monocyte-derived dendritic cells (MDDCs), polymorphonuclear leukocytes (PMN), granulocytes,
eosinophils, CD69
+ cells, CD19
+ cells, CD56
+ cells, CD4
+CD25
high cells, CD8
+ cells, CD4
+ cells and mast cells using quantitative real-time PCR. Data are
expressed in relative units compared to U48 RNA.
doi:10.1371/journal.pone.0000610.g003
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dysfunction in psoriasis through the regulation of
SOCS-3 signaling
Epidermal keratinocytes are active participants in the formation of
psoriasis plaques [11]. Psoriatic keratinocytes show abnormal
differentiation and proliferation, have aberrant cell signaling and
produce mediators that contribute to the recruitment and
activation of immune cells [11]. The specific expression of miR-
203 in skin and in keratinocytes (Fig. 2 and 3) as well as its specific
up-regulation in psoriasis (Fig. 1) suggested that this miRNA plays
a role in the regulation of keratinocyte functions. Thus, we next
focused on characterizing miR-203 in more detail.
Since miRNAs exert their effect by regulating the expression of
protein-coding genes, their function can be interpreted as the sum
of the function of the genes they regulate [2]. To understand the
functions of miR-203 we used a two-step sequential approach: (I)
using algorithms based on a systematic analysis of the structural
requirements for target site function in vivo, we predicted genes that
can be regulated by this miRNA (Table S1); (II) we investigated
the biological functions of the predicted target genes. To explore
whether the presence of miR-203 binding sites in the 39
untranslated region (UTR) of mRNAs correlates with gene
function, we determined if putative miR-203 targets contain
significantly more or fewer genes from any given biological process
than expected given the gene ontology (GO) category’s frequency
in the 39UTR database (Figure S1). Out of the several thousand
GO categories, the top significant (p,0.01) target categories were
dominated by processes related to signal transduction, cell cycle,
morphogenesis and cell growth suggesting a role for miR-203 in
the regulation of these biological processes in the skin (Figure S1).
Of note, these GO categories show significant overlap with the
biological processes that are strongly perturbed in the psoriatic
skin lesions [8].
Figure 4. SOCS-3 may be a molecular target of miR-203 posttranscriptional repression. (A) SOCS-3 is an evolutionarily conserved target of miR-203.
The putative targets site of miR-203 is highly conserved among species. The 8mer seed sequence in the 39UTR of SOCS-3 gene corresponding to miR-
203 binding site is underlined. (B) In situ hybridization with LNA-oligonucleotide probes specific to miR-203 in skin sections from healthy skin and
psoriatic lesional skin. Data are representative of 6 healthy and 6 psoriatic individuals. Note strong staining in the suprabasal layers of the epidermis in
psoriatic skin. The expression of SOCS-3 in healthy and psoriasis skin samples was detected using immunohistochemistry. Original magnification
200x. (C) The expression of SOCS-3 in skin from healthy individuals or lesional skin of psoriatic patients was analyzed using Western blot analysis.
SOCS-3 protein levels are expressed as relative units. Bars represent means of SOCS-3 protein levels in healthy skin (n=6) and psoriatic lesional skin
(n=11) 6 SEM. ** p,0.01.
doi:10.1371/journal.pone.0000610.g004
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cytokine signaling-3 (SOCS-3), an evolutionarily conserved high-
score target of miR-203 with a 10-nucleotide complementarity to
the mature, biologically active form of miR-203 in human, mouse,
rat and dog (Table S1, Fig. 4A). SOCS-3 is part of a negative
feedback loop in cytokine signaling inhibiting the activation of
STAT3, a transcription factor whose activation in keratinocytes is
essential for the development of psoriatic plaques [11,12].
However, SOCS-3 has not been associated with psoriasis.
Next, we analyzed the expression pattern of miR-203 and
SOCS-3 in lesional skin of psoriasis patients and in healthy skin
(Fig. 4B). In situ hybridization using LNA-modified nucleotide
probes revealed that miR-203 is expressed in the suprabasal layers
of the epidermis in normal skin, confirming its keratinocyte-
specific expression observed in vitro (Fig. 4B). In comparison to
healthy skin, the expression of miR-203 was increased in psoriatic
lesional skin in all epidermal layers (Fig. 4B), consistent with the
real-time PCR results. Analysis of SOCS-3 protein expression by
immunohistochemistry showed a complementary pattern with the
miR-203 expression (Fig. 4B). SOCS-3 was strongly expressed by
the basal layer of keratinocytes in healthy skin, while it was
suppressed in the epidermis of psoriasis lesions. Down-regulation
of SOCS-3 expression in psoriatic lesional skin was further
confirmed by Western blot analysis, demonstrating a significant
(p,0.01) decrease in SOCS-3 protein levels in psoriatic plaques as
compared to healthy skin (Fig. 4C). Since the decrease of SOCS-3
protein in psoriatic skin could be due to decreased transcriptional
activity of the gene, we analyzed SOCS-3 mRNA levels in
psoriatic and healthy skin. However, quantitative real time PCR
analysis showed no significant difference in SOCS-3 mRNA
expression between psoriatic and healthy skin (data not shown),
suggesting that the down-regulation of SOCS-3 in psoriasis occurs
at the posttranscriptional level.
SOCS-3 deficiency leads to sustained activation of STAT3 in
response to IL-6 [18], a cytokine present in the psoriasis lesions [11].
This suggests that the suppression of SOCS-3 by miR-203 in
psoriatic lesions would in turn lead to constant activation of STAT3.
Indeed,the psoriatichyperplasticepidermis shows increased STAT3
activation and constitutively active STAT3 in keratinocytes leads to
the spontaneous development of psoriasis in transgenic mice [12].
Thus, the up-regulation of miR-203 may have important implica-
tions for psoriasis pathogenesis by preventing the up-regulation of
SOCS-3 in response to cytokines. It is intriguing to speculate that
suppression of SOCS-3 in psoriatic keratinocytes leads to sustained
activation of the STAT3 pathway, leading to the infiltration of
leukocytes and the development of psoriatic plaques.
In addition to the modulation of inflammatory responses,
SOCS-3 has also been implicated in the regulation of keratinocyte
proliferation and differentiation. It has been shown that over-
expression of SOCS-3 in keratinocytes leads to final differentiation
and inhibits serum-stimulated proliferation [19]. MiRNA-mediat-
ed suppression of SOCS-3 expression in keratinocytes may
therefore not only modulate cytokine signaling but also contribute
to keratinocyte hyperproliferation and alteration in keratinocyte
differentiation in psoriatic plaques.
Although here we exemplified SOCS-3 as a target of miR-203
and showed its down-regulated expression in psoriasis, it is not
likely that miR-203 functions in psoriasis are mediated solely
through the suppression of this protein. Instead, the function of
miR-203 can be interpreted as a function of the sum of all of its
target proteins and the consequence of their interactions. Thus,
future research in the forthcoming years will be needed to
understand fully the consequence of the deregulation of miR-203
and other miRNAs in psoriasis.
Taken together, miRNA expression patterns distinguish psori-
asis from healthy skin and from another chronic inflammatory skin
disease, atopic eczema. Results reported here reveal a new layer of
regulatory mechanisms in the pathogenesis of chronic inflamma-
tory skin diseases. Our data suggest that miR-203 plays a specific
role in the pathogenesis of psoriasis by regulating inflammation-,
proliferation- and morphogenesis-associated processes in the skin.
Interestingly, miRNAs have been recently implicated in the
morphogenesis of murine skin [20]. Since miRNAs are master
switches that ultimately affect complex cellular processes and
functions through the regulation of several proteins, miRNA-based
therapies may be more effective than drugs targeting single
proteins. The disease-specific miRNAs identified in our study
represent potential therapeutic targets in the treatment of chronic
skin inflammation.
MATERIALS AND METHODS
Patients
Both patients and healthy controls were of Caucasian origin,
between 18–65 years old. Patients had not received systemic
immunosuppressive treatment or PUVA/solarium/UV, for at
least 1 month, and topical therapy for at least 2 weeks before skin
biopsy. Four-millimeter punch biopsies were taken and snap-
frozen, after written informed consent, from lesional skin of
patients with moderate or severe chronic plaque psoriasis (n=25),
lesional skin of patients with moderate to severe chronic atopic
eczema (n=20), and from non-inflamed, non-irritated skin of
healthy individuals (n=26). The study was approved by the
Stockholm Regional Ethics Committee, and conducted according
to the Declaration of Helsinki’s principles.
Cells
Primary human keratinocytes, dermal fibroblasts and melanocytes
were isolated from healthy skin using standard protocols and
cultured as described [21,22]. Monocytes were isolated from
PBMCs from healthy blood donors (Karolinska University
Hospital Blood Bank, Stockholm, Sweden) using MACS separa-
tion. Immature monocyte-derived dendritic cells (MDDCs) were
generated by culturing separated monocytes in the presence of
GM-CSF (550 IU/ml), and IL-4 (800 IU/ml) (Biosource In-
ternational, Camarillo, CA, USA) for 6 days. CD4
+, CD8
+,
CD4
+CD25
high, CD56
+, CD19
+, and CD69
+ cells were isolated
from peripheral blood mononuclear cells (PBMCs) from healthy
blood donors by FACS sorting using a Becton Dickinson (BD)
FACSAria cell sorting system and BD FACSDiva software v 4.1.2.
Granulocytes and eosinophils were FACS sorted from whole blood
following RBC lysis with ACK lysis buffer.
microRNA microarray and data analysis
Total RNA from lesional skin of psoriasis patients (n=3) and
atopic eczema patients (n=3) and skin of healthy individuals
(n=4) was isolated using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions. Two mgo f
total RNA from each sample were labeled using the miRCUR-
Y
TM Hy3
TM/Hy5
TM labelling kit and hybridized on the
miRCURY
TM LNA Array (v.8.0) (Exiqon, Vedbaek, Denmark).
Signal intensities were normalized using the global Lowess
regression algorithm. For subsequent analysis, we used the log2
of the background-subtracted, normalized median spot intensities
of ratios from the two channels (Hy3/Hy5). To find consistently
differentially expressed genes, the data were subjected to SAM
analysis as described previously [9]. For visualization of differen-
tially expressed miRNAs, a heat map was generated using
MicroRNAs in Skin Inflammation
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reported in the manuscript is described in accordance with
MIAME guidelines and have been deposited at EMBL-EBI
(accession number: E-MEXP-1123).
Quantitative real-time PCR
Total RNA of skin biopsies and cells was extracted using TRIzol
reagent following the manufacturer’s instructions. RNA from 20
different normal human organs was obtained from Ambion
(FirstChoiceH Human Total RNA Survey Panel). Quantification
of miRNAs by TaqManH Real-Time PCR was carried out as
described by the manufacturer (Applied Biosystems, Foster City,
CA). Briefly, 10 ng of template RNA was reverse transcribed using
the TaqManH MicroRNA Reverse Transcription Kit and
miRNA-specific stem-loop primers (Applied Biosystems). 1.5 ml
RT product was introduced into the 20 ml PCR reactions which
were incubated in 384-well plates on the ABI 7900HT thermo-
cycler (Applied Biosystems) at 95uC for 10 min, followed by 40
cycles of 95uC for 15 s and 60uC for 1 min. Target gene
expression was normalized between different samples based on the
values of U48 RNA expression.
In situ hybridization
In situ transcriptional levels of miR-203 were determined on frozen
sections (10 mm) of skin biopsy specimens from six psoriasis
patients and six healthy individuals according to the manufac-
turer’s instructions (Exiqon). Sections were hybridized o/n with
digoxygenin-labeled miRCURY LNA probes (Exiqon) and in-
cubated with anti-digoxygenin antibody conjugated with alkaline
phosphatase for 1 h. Sections were visualized by using BM purple
substrate together with 2 mM levamisole. The color reaction was
performed o/n. We followed the protocol recommended by the
manufacturer (Exiqon). The stained sections were reviewed with
a Zeiss microscope.
Immunohistochemistry
SOCS-3 protein expression was analyzed in skin from 9 psoriasis
patients and 8 healthy control individuals. Cryostat sections (7 mm)
from skin biopsies were stained with the ABC-ELITE (Vector
Laboratories) immunohistochemical staining method, using rabbit
anti-human SOCS-3 (Santa Cruz, USA), following the manufac-
turer’s instructions.
Western blotting
SOCS-3 protein was detected by immunoblotting with a mouse
anti-human SOCS-3 antibody (Alexis Biochemical, Lausen,
Switzerland). The protein levels were visualized by ECL (GE
Healthcare) using horseradish peroxidase–conjugated Protein A/
G (Pierce Chemical Co.)
Statistical analysis
Parametric or nonparametric ANOVA (with Bonferroni’s or
Dunn’s multiple comparisons test), and Student’s t-test were used
to determine the statistical significance of data.
SUPPORTING INFORMATION
Table S1. The evolutionary conserved targets of miR-203. Only
those targets are shown that were predicted by three different
algorithms independently (the intersection of miRanda, PicTar
and TargetScan predictions).
Found at: doi:10.1371/journal.pone.0000610.s001 (0.87 MB TIF)
Figure S1. Significantly enriched Gene Ontology. Putative
targets of miR-203 were identified using TargetScan 3.0
algorithm. The occurrence of GO terms associated with miR-
203 targets were analyzed using the Gene ontology Tree Machine
and the Gene Set Analysis Toolkit (http://bioinfo.vanderbilt.edu/
webgestalt; Vanderbilt University). Each GO category is repre-
sented by two bars. Significantly (p,0.01) enriched GO terms are
labeled with red. The height of the green bar represents the gene
number expected in the GO category based on the reference set
selected (Expected number of genes in a specific GO category for
an interesting gene set=total number of genes in the GO category
for the reference set * Total number of genes in the interesting set/
total number of genes in the reference set). The height of the red
bar represents the number of genes observed in the GO category
and also in the set of putative miR-203 targets.
Found at: doi:10.1371/journal.pone.0000610.s002 (11.65 MB
TIF)
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